Literature DB >> 22506232

The correlation analysis of functional factors and age with duchenne muscular dystrophy.

Il-Young Jung1, Jong Hee Chae, Sue Kyung Park, Je Ho Kim, Jung Yoon Kim, Sang Joon Kim, Moon Suk Bang.   

Abstract

OBJECTIVE: To correlate existing evaluation tools with clinical information on Duchenne muscular dystrophy (DMD) patients following age and to investigate genetic mutation and its relationship with clinical function.
METHOD: The medical records of 121 children with DMD who had visited the pediatric rehabilitation clinic from 2006 to 2009 were reviewed. The mean patient age was 9.9±3.4 years and all subjects were male. Collected data included Brooke scale, Vignos scale, bilateral shoulder abductor and knee extensor muscles power, passive range of motion (PROM) of ankle dorsi-flexion, angle of scoliosis, peak cough flow (PCF), fractional shortening (FS), genetic abnormalities, and use of steroid.
RESULTS: The Brooke and Vignos scales were linearly increased with age (Brooke (y(1)), Vignos (y(2)), age (x), y(1)=0.345x-1.221, R(Brooke) (2)=0.435, y(2)=0.813x-3.079, R(Vignos) (2)=0.558, p<0.001). In relation to the PROM of ankle dorsi-flexion, there was a linear decrease in both ankles (right and left R(2)=0.364, 0.372, p<0.001). Muscle power, Cobb angle, PCF, and FS showed diversity in their degrees, irrespective of age. The genetic test for dystrophin identified exon deletions in 58.0% (69/119), duplications in 9.2% (11/119), and no deletions or duplications in 32.8% (39/119). Statistically, the genetic abnormalities and use of steroid were not definitely associated with functional scale.
CONCLUSION: The Brooke scale, Vignos scale and PROM of ankle dorsi-flexion were partially available to assess DMD patients. However, this study demonstrates the limitations of preexisting scales and clinical parameters incomprehensively reflecting functional changes of DMD patients.

Entities:  

Keywords:  Age; Duchenne muscular dystrophy; Dystrophin; Function; Gene deletion

Year:  2012        PMID: 22506232      PMCID: PMC3309314          DOI: 10.5535/arm.2012.36.1.22

Source DB:  PubMed          Journal:  Ann Rehabil Med        ISSN: 2234-0645


  39 in total

1.  B-type natriuretic peptide and cardiac dysfunction in Duchenne muscular dystrophy.

Authors:  Tayyab Mohyuddin; Irwin B Jacobs; Robert C Bahler
Journal:  Int J Cardiol       Date:  2006-10-31       Impact factor: 4.164

2.  A standardized method for the evaluation of respiratory muscle endurance in patients with Duchenne muscular dystrophy.

Authors:  S Matecki; N Topin; M Hayot; F Rivier; B Echenne; C Prefaut; M Ramonatxo
Journal:  Neuromuscul Disord       Date:  2001-03       Impact factor: 4.296

Review 3.  Cardiopulmonary support in duchenne muscular dystrophy.

Authors:  Josef Finsterer
Journal:  Lung       Date:  2006 Jul-Aug       Impact factor: 2.584

Review 4.  Pathophysiology of duchenne muscular dystrophy: current hypotheses.

Authors:  Nicolas Deconinck; Bernard Dan
Journal:  Pediatr Neurol       Date:  2007-01       Impact factor: 3.372

Review 5.  Interventions for increasing ankle range of motion in patients with neuromuscular disease.

Authors:  Kristy J Rose; Joshua Burns; Danielle M Wheeler; Kathryn N North
Journal:  Cochrane Database Syst Rev       Date:  2010-02-17

6.  The pathogenesis of Duchenne muscular dystrophy: significance of experimental observations.

Authors:  J Elbrink; S K Malhotra
Journal:  Med Hypotheses       Date:  1985-08       Impact factor: 1.538

7.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

Review 8.  Duchenne muscle activity evaluation and muscle function preservation: is it possible a prophylactic strategy?

Authors:  B Palmieri; V Sblendorio; A Ferrari; A Pietrobelli
Journal:  Obes Rev       Date:  2007-11-23       Impact factor: 9.213

9.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.

Authors:  A P Monaco; C J Bertelson; S Liechti-Gallati; H Moser; L M Kunkel
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

10.  Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy.

Authors:  Giovanni Corrado; Alberto Lissoni; Sandro Beretta; Laura Terenghi; Giorgio Tadeo; Giovanni Foglia-Manzillo; Luca M Tagliagambe; Manuela Spata; Mauro Santarone
Journal:  Am J Cardiol       Date:  2002-04-01       Impact factor: 2.778

View more
  8 in total

1.  Patterns of decline in upper limb function of boys and men with DMD: an international survey.

Authors:  Mariska M H P Janssen; Arjen Bergsma; Alexander C H Geurts; Imelda J M de Groot
Journal:  J Neurol       Date:  2014-04-01       Impact factor: 4.849

2.  Relationship between the climbing up and climbing down stairs domain scores on the FES-DMD, the score on the Vignos Scale, age and timed performance of functional activities in boys with Duchenne muscular dystrophy.

Authors:  Lilian A Y Fernandes; Fátima A Caromano; Silvana M B Assis; Michele E Hukuda; Mariana C Voos; Eduardo V Carvalho
Journal:  Braz J Phys Ther       Date:  2014 Nov-Dec       Impact factor: 3.377

3.  Serum creatinine level: a supplemental index to distinguish Duchenne muscular dystrophy from Becker muscular dystrophy.

Authors:  Huili Zhang; Yuling Zhu; Yiming Sun; Yingyin Liang; Yaqin Li; Yu Zhang; Langhui Deng; Xingxuan Wen; Cheng Zhang
Journal:  Dis Markers       Date:  2015-03-17       Impact factor: 3.434

4.  Autonomic Modulation in Duchenne Muscular Dystrophy during a Computer Task: A Prospective Control Trial.

Authors:  Mayra Priscila Boscolo Alvarez; Talita Dias da Silva; Francis Meire Favero; Vitor Engrácia Valenti; Rodrigo Daminello Raimundo; Luiz Carlos Marques Vanderlei; David M Garner; Carlos Bandeira de Mello Monteiro
Journal:  PLoS One       Date:  2017-01-24       Impact factor: 3.240

5.  A New Functional Scale and Ambulatory Functional Classification of Duchenne Muscular Dystrophy: Scale Development and Preliminary Analyses of Reliability and Validity.

Authors:  Jungyoon Kim; Il-Young Jung; Sang Jun Kim; Joong-Yub Lee; Sue Kyung Park; Hyung-Ik Shin; Moon Suk Bang
Journal:  Ann Rehabil Med       Date:  2018-10-31

6.  HLA Polymorphism Affects Risk of de novo Mutation of dystrophin Gene and Clinical Severity of Duchenne Muscular Dystrophy in a Southern Chinese Population.

Authors:  Huan Li; Lulu Xiao; Liang Wang; Jinfu Lin; Min Luo; Menglong Chen; Ruojie He; Yuling Zhu; Cheng Zhang
Journal:  Front Neurol       Date:  2018-11-15       Impact factor: 4.003

7.  Quality of life and informal care burden associated with duchenne muscular dystrophy in Portugal: the COIDUCH study.

Authors:  Valeska Andreozzi; Pedro Labisa; Melina Mota; Susana Monteiro; Rita Alves; João Almeida; Björn Vandewalle; Jorge Felix; Katharina Buesch; Hugo Canhão; Igor Beitia Ortiz de Zarate
Journal:  Health Qual Life Outcomes       Date:  2022-03-03       Impact factor: 3.186

8.  Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study.

Authors:  Pedro Labisa; Valeska Andreozzi; Melina Mota; Susana Monteiro; Rita Alves; João Almeida; Björn Vandewalle; Jorge Felix; Katharina Buesch; Hugo Canhão; Igor Beitia Ortiz de Zarate
Journal:  Pharmacoecon Open       Date:  2021-10-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.